| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-379 | |
| Phytochemical name or plant extracts | Martynoside | |
| PMID | 16198557 | |
| Literature evidence | Our study suggests that the nature is rich in selective ERalpha and ERbeta ligands, the discovery of which may lead to the development of novel neutraceutical agents. | |
| IUPAC name | [(2R,3R,4R,5R,6R)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate | |
| Phytochemicals’ class or type of plant extracts | Glycoside | |
| Source of phytochemicals or plant Extracts | Ajuga chamaecistus | |
| Geographical availability | Afghanistan, Iran | |
| Plant parts | Aerial parts | |
| Other cancers | Breast cancer | |
| Target gene or protein | ICI182780, IGFBP3 | |
| Gene or Protein evidence | Martynoside was a potent antiestrogen in MCF-7 cells, increasing, like ICI182780, IGFBP3 levels via the ER-pathway. | |
| Target pathways | ER-pathway | |
| IC50 | NA | |
| Potency | In osteoblasts, martynoside induced nodule mineralization, which was abolished by ICI182780, implicating an ER-mediated mechanism. Furthermore, its antiproliferative effect on endometrial cells suggests that martynoside may be an important natural SERM. | |
| Cell line/ mice model | MCF-7 | |
| Additional information | NA | |
| PubChem ID | 5319292 | |
| Additional PMIDs | 16198557 22888532 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:444545-1 | |
| Safety | NA |